A retrospective clinical study of mortality according to hemoglobin levels and administration of calcimimetics and erythropoietin stimulating agents in dialysis patients.

A retrospective clinical study of mortality according to hemoglobin levels and administration of calcimimetics and erythropoietin stimulating agents in patients on hemodialysis using dialyzers with beta2-microglobulin clearance of more than 70 mL/min and on online hemodialfiltration. - Influence of mortality according to hemoglobin levels and administration of calcimimetics and erythropoietin stimulating agents in HD using dialyzers with beta2-microglobulin clearance of more than 70 mL/min and OHDF.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000057577

Enrollment

738

Registered

2026-03-31

Start date

2025-04-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with end-stage kidney disease undergoing hemodialysis and online hemodiafiltration

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients on maintenance hemodialysis or online hemodialysis as of July 1, 2017

Exclusion criteria

Exclusion criteria: 1 Use of dialyzers with beta2-microgloburln clearance below 70 mL/min 2 Missing data for covariates at study entry 3 Dialysis conditionssuch as dialysis method and membrane material between April 1, 2017 and June 30, 2017, which are different from those as of July 1, 2017 4 Blood purification methods other than hemodialysis and online hemodiafiltration 5 Dialysis frequency below 3 sessions per week or dialysis time below 3 hour per session 6 pre-OHDF substitution volume of <60 L and post-OHDF substitution volume of <8 L 7 Cases <20 years old 8 For propensity score matching, Hb <10g/dL and >12.9g/dL

Design outcomes

Primary

Measure	Time frame
2-year all-cause mortality	—

Countries

Japan

Contacts

Public ContactManabu Tashiro

Social medical corporation Kawashimakai Kawashima Hospital Department of Nephrology

m.tashiro@khg.or.jp08081571675

Outcome results